Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2024

Open Access 07-03-2024 | Cytostatic Therapy | REVIEW

Metronomic Chemotherapy in Elderly Patients

Authors: Arianna Bandini, Pasquale Fabio Calabrò, Marta Banchi, Paola Orlandi, Guido Bocci

Published in: Current Oncology Reports | Issue 4/2024

Login to get access

Abstract

Purpose of Review

This review describes the most relevant studies found in the scientific literature regarding metronomic chemotherapy (MCT) in the geriatric oncology population to support its use as a feasible treatment of care in the frail elderly patients.

Recent Findings

Recent years have seen a reevaluation of cancer chemotherapeutic drugs and MCT is an emerging schedule in phase II and III clinical trials.

Summary

Ageing is one of the risk factors for the development of cancer, the incidence of whom increases dramatically in people who live longer. To date, standard oncological protocols involve chemotherapeutic drugs in short cycles of therapy at the maximum tolerated dose (MTD). Although these therapeutic regimens may be successful, they can cause important adverse drug reactions, especially in elderly or frail patients. MCT is a different modality of delivery of chemotherapeutic drugs (frequent low dose for prolonged time) and it looks at the overcoming of the limitations and disadvantages of MTD, in particular the toxicity aspect. We reviewed the experience of clinicians who have used MCT in clinical trials enrolling elderly patients with different cancer types.
Literature
1.
2.
Scotté F, Bossi P, Carola E, Cudennec T, Dielenseger P, Gomes F, et al. Addressing the quality of life needs of older patients with cancer: A SIOG consensus paper and practical guide. Ann Oncol. 2018;29:1718–26.PubMedCrossRef
3.
Kumar Pal S, Katheria V, Hurria A. Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment. CA Cancer J Clin. 2010;60:120–32.CrossRef
4.
Bellelli F, Consorti E, Hettiarachchige TMK, Rossi P, Lucchi T, Froldi M, et al. Relationship among age, education and frailty in older persons. J Frailty Aging. 2023;12:326–8.PubMed
5.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. The Lancet. 2013;381:752–62.CrossRef
6.
Kareva I, Waxman DJ, Klement GL. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015;358:100–6.PubMedCrossRef
7.••
Tralongo AC, Fratamico RS, Russo C, Sbrana A, Antonuzzo A, Danova M. Anti-cancer treatment strategies in the older population: Time to test more? Geriatrics. 2021;6:42. This article highlights the limitations and critical issues of antineoplastic therapies traditionally used to treat elderly cancer patients (including MTD), emphasizing the advantages of using MCT and encouraging its use to improve the management of the geriatric cancer population.PubMedPubMedCentralCrossRef
8.••
Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: A neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13:659–73. This article highlighted the main features of MCT, describing its pharmacokinetic and pharmacodynamic profiles that have emerged from various preclinical and clinical studies.PubMedCrossRef
9.
Kim J, Kim YM. Tumor endothelial cells as a potential target of metronomic chemotherapy. Arch Pharm Res. 2019;42:1–13.PubMedCrossRef
10.
Wildiers H. Mastering chemotherapy dose reduction in elderly cancer patients. Eur J Cancer. 2007;43:2235–41.PubMedCrossRef
11.
Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938–43.PubMed
12.
Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003;100:12917–22.PubMedPubMedCentralCrossRef
13.
Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–86.PubMed
14.
Panthi VK, Dua K, Singh SK, Gupta G, Hansbro PM, Paudel KR. Nanoformulations-based metronomic chemotherapy: mechanism, challenges, recent advances, and future perspectives. Pharmaceutics. 2023;15:1192.PubMedPubMedCentralCrossRef
15.
Natale G, Bocci G. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data. Cancer Lett. 2018;432:28–37.PubMedCrossRef
16.
Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer. 2018;118:1329–36.PubMedPubMedCentralCrossRef
17.
18.
Muthusamy P, Chary KV, Nalini GK. Metronomic chemotherapy: Seems prowess to battle against cancer in current scenario. J Clin Diagn Res. 2016;10:FC09-FC13.
19.
Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, et al. Cyclophosphamide-methotrexate “metronomic” chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Annal Oncol. 2005;16:1243–52.CrossRef
20.
Cazzaniga ME, Munzone E, Bocci G, Afonso N, Gomez P, Langkjer S, et al. Pan-European expert meeting on the use of metronomic chemotherapy in advanced breast cancer patients: The Penelope project. Adv Ther. 2019;36:381–406.PubMedCrossRef
21.
22.
Banchi M, Lanzolla T, Di Napoli A, Bandini A, Bocci G, Cox MC. Complete remission of a diffuse large B-cell lymphoma in a young patient, with severe tuberous sclerosis, treated with metronomic chemotherapy and ibrutinib: a case report. Chemotherapy. 2023:1–5.
23.
Riesco-Martinez M, Parra K, Saluja R, Francia G, Emmenegger U. Resistance to metronomic chemotherapy and ways to overcome it. Cancer Lett. 2017;400:311–8.PubMedPubMedCentralCrossRef
24.•
Sureshkumar K, Srinivasan K, Lingeshwaran GP, Durairaj M, Thiruvengadam G, Mary Martin Daniel PJ, et al. Toxicity profile, adverse drug reactions and drug-drug interactions among geriatric cancer patients under metronomic chemotherapy in a South Indian tertiary care hospital. J Oncol Pharm Pract. 2023;29:778–84. This study examined the toxicity profile and drug-drug interactions in elderly geriatric cancer patients receiving MCT.PubMedCrossRef
25.
Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, et al. Global increase in breast cancer incidence: risk factors and preventive measures. Biomed Res Int. 2022;2022:9605439.PubMedPubMedCentralCrossRef
26.
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438–51.PubMedCrossRef
27.
Di Desidero T, Xu P, Man S, Bocci G, Kerbel RS. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget. 2015;6:42396–410.PubMedPubMedCentralCrossRef
28.
De Iuliis F, Salerno G, Taglieri L, Lanza R, Scarpa S. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori. 2015;101:30–5.PubMedCrossRef
29.•
Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018;19:323–36. This multicenter, open-label, randomized, phase 2 study in 30 centers in eight European countries compared the efficacy of anti-HER2 treatment with or without MCT in elderly patients with HER2-positive metastatic breast cancer.PubMedCrossRef
30.
Krajnak S, Decker T, Schollenberger L, Rosé C, Ruckes C, Fehm T, et al. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046. J Cancer Res Clin Oncol. 2021;147:3391–400.PubMedPubMedCentralCrossRef
31.
Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer. 2010;10:301–6.PubMedCrossRef
32.
Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, et al. Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study. Tumori. 2017;103:e4–8.PubMedCrossRef
33.
Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006;24:3623–8.PubMedCrossRef
34.
Crivellari D, Gray KP, Dellapasqua S, Puglisi F, Ribi K, Price KN, et al. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen” : The CASA randomized trial. Breast. 2013;22:130–7.PubMedCrossRef
35.
Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R, Bocci G. Metronomic chemotherapy for metastatic prostate cancer: A “young”concept for old patients? Drugs Aging. 2010;27:689–96.PubMedCrossRef
36.
Parshad S, Sidhu AK, Khan N, Naoum A, Emmenegger U. Metronomic chemotherapy for advanced prostate cancer: A literature review. J Clin Med. 2022;11:2783.PubMedPubMedCentralCrossRef
37.
38.
Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med. 2004;351:1513–20.PubMedCrossRef
39.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med. 2004;351:1502–12.CrossRef
40.•
Fontana A, Bocci G, Galli L, D’Arcangelo M, Derosa L, Fioravanti A, et al. Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J Am Geriatr Soc. 2010;58:986–8. This retrospective study emphasized the efficacy and favorable toxicity profile of MCT in the treatment of mCRPC in elderly patients.
41.
Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62:2731–5.PubMed
42.
Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res. 2009;15:4954–62.PubMedCrossRef
43.
Tralongo P, Bordonaro S, Di Mari A, Cappuccio F, Rametta GS. Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience. Prostate Int. 2016;4:15–9.PubMedPubMedCentralCrossRef
44.
Tagliamento M, Frelaut M, Baldini C, Naigeon M, Nencioni A, Chaput N, et al. The use of immunotherapy in older patients with advanced non-small cell lung cancer. Cancer Treat Rev. 2022;106:102394.PubMedCrossRef
45.
Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7.PubMedCrossRef
46.
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv192–237.
47.
Camerini A, Banna GL, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F, et al. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis. Clin Transl Oncol. 2019;21:790–5.PubMedCrossRef
48.
Estevinho F, Gomes R, Hasmucrai D, Barata F. Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients. Pulmonology. 2022;28:368–75.PubMedCrossRef
49.
Orlandi P, Di Desidero T, Salvia G, Muscatello B, Francia G, Bocci G. Metronomic vinorelbine is directly active on non small cell lung cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors. Biochem Pharmacol. 2018;152:327–37.PubMedCrossRef
50.
Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: A hellenic cooperative oncology group clinical translational study. BMC Cancer. 2013;13:263.PubMedPubMedCentralCrossRef
51.
Gironés Sarrió R, Antonio Rebollo M, Molina Garrido MJ, Guillén-Ponce C, Blanco R, Gonzalez Flores E, et al. General recommendations paper on the management of older patients with cancer: the SEOM geriatric oncology task force’s position statement. Clin Transl Oncol. 2018;20:1246–51.PubMedPubMedCentralCrossRef
52.
Pasini F, Barile C, Caruso D, Modena Y, Fraccon AP, Bertolaso L, et al. Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world. Invest New Drugs. 2018;36:927–32.PubMedCrossRef
53.•
D’D’Ascanio M, Pezzuto A, Fiorentino C, Sposato B, Bruno P, Grieco A, et al. metronomic chemotherapy with vinorelbine produces clinical benefit and low toxicity in frail elderly patients affected by advanced non-small cell lung cancer. Biomed Res Int. 2018;2018:6278403. This study confirmed the efficacy in controlling cancer progression and good safety profile of metronomic VNR administered at different doses in elderly advanced NSCLC patients.
54.
Di M, Huntington SF, Olszewski AJ. Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist. 2021;26:120–32.PubMedCrossRef
55.•
Cox MC, Banchi M, Pelliccia S, Di Napoli A, Marcheselli L, Patti C, et al. All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma. Cancer Chemother Pharmacol. 2020;86:841–6. In this multicenter study the DEVEC schedule showed encouraging activity and acceptable toxicity for the treatment of elderly PTCL patients.
56.
Cox MC, Bocci G. Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds. Cancer Lett. 2022;524:144–50.PubMedCrossRef
57.••
Cox MC, Musuraca G, Battistini R, Casaroli I, Zoli V, Anticoli-Borza P, et al. Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit. Br J Haematol. 2018;183:819–22. In this study the metronomic DEVEC program was found to be active and well tolerated in aggressive type B and T lymphomas, even in very elderly patients unfit for standard therapy.PubMedCrossRef
58.
Rozados VR, Sánchez AM, Gervasoni SI, Berra HH, Matar P, Scharovsky OG. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Ann Oncol. 2004;15:1543–50.PubMedCrossRef
59.
Witte HM, Riecke A, Mayer T, Bartscht T, Rades D, Lehnert H, et al. Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2019;145:129–36.PubMedCrossRef
60.
Schelker RC, Herr W, Reichle A, Vogelhuber M. Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: A single center experience. BMC Cancer. 2018;18:1000.PubMedPubMedCentralCrossRef
61.
Zeng J, Yang L, Huang F, Hong T, He Z, Lei J, et al. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymp. Cancer Chemother Pharmacol. 2016;78:801–8.PubMedCrossRef
62.
Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma. 2008;49:447–50.PubMedCrossRef
63.
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460–8.PubMedCrossRef
64.
Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4:e46–55.PubMedCrossRef
65.
Cox MC, Pelliccia S, Marcheselli L, Battistini R, Arcari A, Borza PA, et al. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. Invest New Drugs. 2019;37:548–58.PubMedCrossRef
66.••
Bocci G, Pelliccia S, Orlandi P, Caridi M, Banchi M, Musuraca G, et al. Remarkable remission rate and long-term efficacy of upfront metronomic chemotherapy in elderly and frail patients, with diffuse large B-cell lymphoma. J Clin Med. 2022:11. This multicenter study confirmed that the oral metronomic protocol DEVEC exerts an effective pharmacological activity on cancer cells that allows to obtain a lasting remission and long-term effectiveness, with acceptable toxicity and good tolerability in elderly and fragile patients with DLBCL.
67.
Fante MA, Harrer DC, Zartner B, Lüke F, Mayer S, Menhart K, et al. All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma. Front Oncol. 2023;13:1177330.PubMedPubMedCentralCrossRef
68.
Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010;116:2655–64.PubMedCrossRef
69.
Borne E, Desmedt E, Duhamel A, Mirabel X, Dziwniel V, Maire C, et al. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs. 2010;28:684–9.PubMedCrossRef
70.
Dinkic C, Eichbaum M, Schmidt M, Grischke EM, Gebauer G, Fricke HC, et al. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. Gynecol Oncol. 2017;146:279–84.PubMedCrossRef
71.
He S, Shen J, Hong L, Niu L, Niu D. Capecitabine “metronomic” chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol. 2012;29:100–6.PubMedCrossRef
72.
Liu J, Wang Y, Jiang H, Yu X, Xu N. Long-term survival of an elderly female with metastatic colon cancer after treated with capecitabine monotherapy. Medicine. 2019;98:e14326.PubMedPubMedCentralCrossRef
73.
Muratori L, La SA, Gorzegno G, Sperone P, Scagliotti GV. Long-term disease control in a metastatic squamous cell carcinoma of the oral cavity treated with maintenance metronomic capecitabine. J Oncol Pharm Pract. 2020;26:240–3.PubMedCrossRef
74.
Phinyo P, Patumanond J, Pongudom S. Time-dependent treatment effects of metronomic chemotherapy in unfit AML patients: a secondary analysis of a randomised controlled trial. BMC Res Notes. 2021;14:3.PubMedPubMedCentralCrossRef
75.
Hartmann JT, Kopp HG, Gruenwald V, Piperno-Neumann S, Kunitz A, Hofheinz R, et al. Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. Eur J Cancer. 2020;124:152–60.PubMedCrossRef
Metadata
Title
Metronomic Chemotherapy in Elderly Patients
Authors
Arianna Bandini
Pasquale Fabio Calabrò
Marta Banchi
Paola Orlandi
Guido Bocci
Publication date
07-03-2024
Publisher
Springer US
Published in
Current Oncology Reports / Issue 4/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01505-w

Other articles of this Issue 4/2024

Current Oncology Reports 4/2024 Go to the issue

REVIEW

Lymph node dissection in testicular cancer

REVIEW

Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas

REVIEW

Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?

REVIEW

Integrated care in breast cancer

REVIEW

Oral Complications and Management Strategies for Cancer Patients: Principles of Supportive Oncology in Dentistry

REVIEW

Update on the management of bone metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits